

CIN NO.: L24230WB1982PLC034492

Date: - 18th April, 2024

To. The Secretary, The Calcutta Stock Exchange Limited 7, Lyons Range, Kolkata - 700 001

Dear Sir/Madam,

Sub: Compliance Report on Corporate Governance for the 04th Quarter and Year ended March 31, 2024

We attach herewith the quarterly compliance report on Corporate Governance as per Regulation 27(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in the format (Annexure I, II & 1V) for the 04th Quarter and Year ended March 31, 2024.

The above reports shall be placed before the Board of Directors in its forthcoming meeting.

Please acknowledge the receipt of the same and take on record.

Yours faithfully,

For Adinath Bio-Labs Limited

Digitally signed by YAMINI YAMINI GULERIA GULERIA Date: 2024.04.18 17:50:07 +05'30'

Yamini Guleria **Company Secretary cum Compliance Officer** M. No: 50370



Encl. As Above

Format to be submitted by listed entity on quarterly basis

1. Name of Listed Entity : Adinath Bio-Labs Limited

2. Quarter ending : 31st March, 2024

I. (. Composition of Board of Directors											
Title (Mr. / Ms)	Name of the Director	PAN\$ & DIN	Category (Chairperson/ Executive/Non - Executive/Independ ent/&Nominee)	Initial Date of Appointment	Date of Reappointment	Date of cessation	Tenur e* (in mont hs)	Date of Birth	No of Directorshi p in listed entities including this listed entity (Refer Regulation 17 A (1) of Listing Regulations)	Directorship in listed entities including this listed entity [In reference to proviso to regulation 17A(1)]	Committee (s) Including this listed entity	No of post of Chairperson in Audit/Stakeho Ider Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)
Mr.	Sunil Kumar	PAN: BUNPK7659F DIN: 07777351	Whole Time Director	04/08/2023			ı	02/03/1971	1	0	0	0
Mr.	Sanjoy Kumar Basu	PAN: BBRPB2936H DIN: 10172874	Non-Executive Director (Chairman)	26/07/2023			-	02/11/1976	1	0	2	0
Mr.	Manoj Kumar	PAN: BJEPK4202J DIN: 03083206	Non-Executive – Independent Director	01/10/2020			42	28/02/1984	3	3	6	0
Mrs.	Priti Abhay Vakhare		Non-Executive – Independent Director	05/02/2021			38	05/09/1982	2	2	4	2
Mr.	Vivek Rana	PAN:AYQPR6603N	Chief Finance Officer	15/04/2019			NA	12/12/1978	-	-	-	-
		PAN: BLJPG8054K	Company Secretary	12/08/2019			NA	11/03/1988		-	-	-
	ether Regular chairpo				YES							
Wh	Whether Chairperson is related to managing director or CEO			NO								

^{\$}PAN of any director would not be displayed on the website of Stock Exchange

[&]amp;Category of directors means executive/non-executive/independent/Nominee. if a director fits into more than one category write all categories separating them with hyphen

* to be filled only for Independent Director. Tenure would mean total period from which Independent director is serving on Board of directors of the listed entity in continuity without any cooling period.




Name of Committee	Whether Regular chairperson appointed	Name of Committee members	Category (Chairperson/Executive/Non- Executive/independent/Nominee) \$	Date of Appointment	Date of Cessation
1. Audit Committee	Yes	Mrs. Priti Abhay Vakhare	Non-Executive - Independent Director (Chairperson)	05-02-2021	
		Mr. Sanjoy Kumar Basu	Non-Executive Director	26-07-2023	
		Mr. Manoj Kumar	Non-Executive - Independent Director	10-11-2020	
2. Nomination & Remuneration	Yes	Mrs. Priti Abhay Vakhare	Non-Executive - Independent Director (Chairperson)	05-02-2021	
Committee		Mr. Sanjoy Kumar Basu	Non-Executive Director	26-07-2023	
		Mr. Manoj Kumar	Non-Executive - Independent Director	10-11-2020	
3. Risk Management Committee (if	Yes	Mrs. Priti Abhay Vakhare	Non-Executive - Independent Director (Chairperson)	05-02-2021	
applicable)		Mr. Sanjoy Kumar Basu	Non-Executive Director	26-07-2023	
		Mr. Manoj Kumar	Non-Executive - Independent Director	10-11-2020	
4. Stakeholders Relationship Committee	Yes	Mrs. Priti Abhay Vakhare	Non-Executive - Independent Director (Chairperson)	05-02-2021	
		Mr. Sanjoy Kumar Basu	Non-Executive Director	26-07-2023	
		Mr. Manoj Kumar	Non-Executive - Independent Director	10-11-2020	

III. Meeting of Board of Directors									
Date(s) of Meeting (if any) in Date(s) of Meeting (if any) in Whether requirement of Number of Directors Number of independent Maximum gap between any two									
the previous quarter	the relevant quarter	Quorum met*	present*	directors present*	consecutive (in number of days)				
November 03, 2023 February 03, 2024 Yes 4 2 91 Days									
* to be filled in only for the curren	* to be filled in only for the current quarter meetings								

IV. Meeting of Committees								
Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (details)*	Number of Directors present*	Number of independent directors present*	Date(s) of meeting of the committee in the previous quarter	Maximum gap between any two consecutive meetings in number of days*			
Audit Committee February 03, 2024	Yes – All Members Present	3	2	November 03, 2023	91 Days			
Risk Management Committee February 03, 2024	Yes – All Members Present	3	2	November 03, 2023	91 Days			
Stakeholders Relationship Committee Nil	Yes – All Members Present	3	2	November 03, 2023	NA			
Independent Directors Committee February 03, 2024	Yes – All Members Present	2	2	Nil	NA			

^{*} This information has to be mandatorily be given for audit committee, for rest of the committees giving this information is optional



^{**}to be filled in only for the current quarter meetings

V. Related Party Transactions	
Subject	Compliance status (Yes/No/NA) refer note below
Whether prior approval of audit committee obtained	NA
Whether shareholder approval obtained for material RPT	NA
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	NA

Note

1 In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A.

For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.

2 If status is "No" details of non-compliance may be given here.

Details of Cyber Security Incidence							
Whether as per Regulations 27(2)(ba)of SEBI (documents during the Quarter	NO						
Date of Event	NA						

VI. Affirmations

- 1. The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 2. The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015
 - a. Audit Committee
 - b. Nomination & remuneration committee
 - c. Stakeholders relationship committee
 - d. Risk management committee (applicable to the top 1000 listed entities)
- 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 4. The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 5. This report and/or the report submitted in the previous quarter has been placed before Board of Directors. Any comments/observations/advice of Board of Directors may be mentioned here:

For Adinath Bio-Labs Limited

YAMINI GULERIA Digitally signed by YAMINI GULERIA Date: 2024.04.18 17:51:04 +05'30'

Yamini Guleria

Company Secretary cum Compliance Officer

M. No: 50370

Company Secretary and Compliance Officer / Managing Director/Whole Time Director/CEO /CFO

Note:

Information at Table I and II above need to be necessarily given in 1st quarter of each financial year. However if there is no change of information in subsequent quarter(s) of that financial year, this information may not be given by Listed entity and instead a statement "same as previous quarter" may be given.

Format to be submitted by listed entity at the end of the financial year 31/03/2024 (for the whole of financial year)

Item	(Yes/No/NA) refer note below	Web address		
Details of business	Yes	https://www.adinathbio.com/SEBI_LODR.html		
Terms and conditions of appointment of independent directors	Yes	https://www.adinathbio.com/SEBI_LODR.html		
Composition of various committees of board of directors	Yes	https://www.adinathbio.com/SEBI_LODR.html		
Code of conduct of board of directors and senior management personnel	Yes	https://www.adinathbio.com/SEBI_LODR.html		
Details of establishment of vigil mechanism/ Whistle Blower policy	Yes	https://www.adinathbio.com/SEBI_LODR.html		
Criteria of making payments to non-executive directors	Yes	https://www.adinathbio.com/SEBI_LODR.html		
Policy on dealing with related party transactions	Yes	https://www.adinathbio.com/SEBI_LODR.html		
Policy for determining 'material' subsidiaries	Yes	https://www.adinathbio.com/SEBI_LODR.html		
Details of familiarization programmes imparted to independent directors	Yes	https://www.adinathbio.com/SEBI_LODR.html		
email address for grievance redressal and other relevant details	Yes	https://www.adinathbio.com/SEBI_LODR.html		
Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes	https://www.adinathbio.com/SEBI_LODR.html		
Financial results	Yes	https://www.adinathbio.com/SEBI_LODR.html		
Shareholding pattern	Yes	https://www.adinathbio.com/SEBI_LODR.html		
Details of agreements entered into with the media companies and/or their associates	N.A.			
Schedule of analyst or institutional investors meet and presentation made by the listed by the listed entity to analyst or institutional investors simultaneously with submission to Stock Exchange	N.A.			
Audio or video recordings and transcripts of post earnings/quarterly calls	N.A.			
New name and the old name of the listed entity	N.A.			
Advertisement as per regulation 47(1)	Yes	https://www.adinathbio.com/SEBI_LODR.html		
Credit rating or revision in credit rating obtained	N.A.	3,500		
Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year	N.A.	YAMINI GULERIA Digitally signed by YAMINI GULERIA Date: 2024.04.18 17:52:33 +05'30'		
Secretarial Compliance Report	Yes	https://www.adinathbio.com/SEBI_LODR.html		
Materiality Policy as per Regulation 30(4)	Yes	https://www.adinathbio.com/SEBI_LODR.html		

Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as required under regulation 30(5)			https://www.adinathbio.com/SEBI_LODR.html
Disclosures under regulation 30(8)	Yes		https://www.adinathbio.com/SEBI_LODR.html
Statements of deviation(s) or variations(s) as specified in regulation 32	N.A		
Dividend Distribution policy as per Regulation 43A(1)	N.A		
Annual return as provided under section 92 of the Companies Act, 2013	Yes		https://www.adinathbio.com/SEBI_LODR.html
Confirmation that the above disclosures are in a separate section as specified in regulation 46(2)	Yes		https://www.adinathbio.com/SEBI_LODR.html
Compliance with regulation 46(3) with respect to accuracy of disclosures on the website and timely updating Disclosure of notes on website in terms	Yes		https://www.adinathbio.com/SEBI_LODR.html
Regulations explanatory [Text Block]	S 01 L	isting	
II Annual Affirmations			
Particulars		Regulation Number	Compliance status (Yes/No/NA) refer note below
Independent director(s) have been appointed in terms of specified criteria (independence' and/or 'eligibility'	of	16(1)(b) & 25(6)	Yes
Board composition		17(1), 17(1A) & 17(1C), 17(1D) & 17(1E)	Yes
Meeting of Board of directors		17(2)	Yes
Quorum of Board meeting		17(2A)	Yes
Review of Compliance Reports		17(3)	Yes
Plans for orderly succession for appointments		17(4)	Yes
Code of Conduct		17(5)	Yes
Fees/compensation		17(6)	Yes
Minimum Information		17(7)	Yes
Compliance Certificate		17(8)	Yes
Risk Assessment & Management Performance Evaluation of Independent Directors	t	17(9) 17(10)	Yes Yes
Recommendation of the Board		17(11)	Yes
Maximum numbers of Directorship		17(A)	Yes
Composition of Audit Committee		18(1)	Yes
Meeting of Audit Committee		18(2)	Yes
Role of Audit Committee and information to be reviewed by the audit committee	on	18(3)	Yes
Composition of nomination & remuneration committee		19(1) & (2)	Yes
Quorum for Nomination and Remuneration Committee		19(2A)	Yes
Meeting of Nomination and Remuneration Committee		19(3A)	Yes
Role of Nomination and Remuneration Committee		19(4)	Yes BIO-
Composition of Stakeholder Relationship Committee		20(1), (2) & 20(2A)	Yes
Meeting of Stakeholder Committee Meeting		20(3A)	Yes
Role of Stakeholders Relationship		20(4)	Yes
			YAMINI Digitally signed by YAMINI GULERIA Date: 2024.04.18 17:52.04+0530'

Committee		
Composition and role of risk management	21(1),(2),(3),(4)	Yes
committee Meeting of Risk Management Committee	21(3A)	Yes
Meeting		
Quorum of Risk Management Committee meeting	21(3B)	Yes
Gap between the meetings of the Risk Management Committee	21(3C)	Yes
Vigil Mechanism	22	Yes
Policy for related party Transaction	23(1), (1A),(5),(6),(7) & (8)	Yes
Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes
Approval for material related party transactions	23(4)	N.A.
Disclosure of related Party Transaction on consolidated basis	23(9)	Yes
Composition of Board of Directors of unlisted material Subsidiary	24(1)	N.A.
Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4),(5) & (6)	N.A.
Alternate Director to Independent Director	25(1)	N.A.
Maximum Directorship & Tenure	25 (2)	Yes
Appointment, Re-appointment or removal of an Independent Director through special resolution or the alternate mechanism	25(2A)	Yes
Meeting of independent directors	25(3) & (4)	Yes
Familiarization of independent directors	25(7)	Yes
Declaration From Independent Director	25(8) & (9)	Yes
Directors and Officers insurance	25(10)	N.A.
Confirmation with respect to	25(11)	Yes
appointment of Independent Directors who resigned from the listed entity	23(11)	ies
Memberships in Committees	26(1)	Yes
Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes
Disclosure of Shareholding by Non- Executive Directors	26(4)	NA
Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes
Approval of the Board and shareholders for compensation or profit sharing in connection with dealings in the securities of the listed entity	26(6)	NA
Vacancies in respect Key Managerial Personnel	26A(1) & 26A(2)	Yes
Note		
1 In the column "Compliance Status", c	compliance or non-	

- 1 In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.
- $2\,$ $\,$ If status is "No" details of non-compliance may be given here.
- 3 If the Listed Entity would like to provide any other



information the same may be indicated here.	
III Affirmations:	
The Listed Entity has approved Material Subsidiary Policy	
and the Corporate Governance requirements with respect to	
subsidiary of Listed Entity have been complied. NA	
For Adinath Bio-Labs Limited	
YAMINI Digitally signed by YAMINI GULERIA	810-
GULERIA Date: 2024.04.18 17:51:32 +05'30'	15 14 M
	70
Yamini Guleria	KOLKATA (")
M. No: 50370	
Company Secretary cum Compliance Officer / Managing Director/Whole-Time Director/ CEO /CFO	
Director/ Whole-Time Director/ CEO / CFO	*

Format to be submitted twice a year on a half yearly basis by listed entity at the end of every 6 months of the financial year

1. Name of Listed Entity : Adinath Biolabs Limited

2. Half Year ending : 31st March, 2024

I. Disclosure of Loans / guarantees / comfort letters / securities etc.

A. Any loan or any other form of debt advanced by the listed entity directly or indirectly to:

Entity	Aggregate amount advanced during six months	Balance outstanding at the end of six months
Promoter or any other entity controlled by them	Nil	Nil
Promoter Group or any other entity controlled by them	Nil	Nil
Directors (including relatives) or any other entity controlled by them	Nil	Nil
KMPs or any other entity controlled by them	Nil	Nil

B. Any guarantee/ comfort letter (by whatever name called) provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by:

Entity	Type (guarantee, comfort letter etc.)	Aggregate amount of issuance during six months	Balance outstanding at the end of six months (taking into account any invocation)
Promoter or any other entity controlled by them	Nil	Nil	Nil
Promoter Group or any other entity controlled by them	Nil	Nil	Nil
Directors (including relatives) or any other entity controlled by them	Nil	Nil	Nil
KMPs or any other entity controlled by them	Nil	Nil 810	Nil



C. Any security provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by:

Entity	Type of security (cash, shares etc.)	Aggregate value of security provided during six months	Balance outstanding at the end of six months
Promoter or any other entity controlled by them	Nil	Nil	Nil
Promoter Group or any other entity controlled by them	Nil	Nil	Nil
Directors (including relatives) or any other entity controlled by them	Nil	Nil	Nil
KMPs or any other entity controlled by them	Nil	Nil	Nil

II. Affirmations:

All loans (or other form of debt), guarantees, comfort letters (by whatever name called) or securities in connection with any loan(s) (or other form of debt) given directly or indirectly by the listed entity to promoter(s), promoter group, director(s) (including their relatives), key managerial personnel (including their relatives) or any entity controlled by them are in the economic interest of the company.



- 1. These disclosures shall exclude any loan (or other form of debt), guarantee / comfort letter (by whatever name called) or security provided in connection with any loan or any other form of debt;
 - a) by a government company to/ for the Government or government company
 - b) by the listed entity to/for its subsidiary [and joint-venture company] whose accounts are consolidated with the listed entity.
 - c) by a banking company or an insurance company; and
 - d) by the listed entity to its employees or directors as a part of the service conditions
- 2. If the Listed Entity would like to provide any other information, the same may be indicated as Para D in the above table.